Yatırımcı.AI

BISTTRY13:44Live

Gen İlaç ve Sağlık Ürünleri Sanayi ve Ticaret A.Ş.

GENIL Stock Analysis and CommentaryGen İlaç ve Sağlık Ürünleri Sanayi ve Ticaret A.Ş.

Main MarketChemicals, Petroleum, Rubber and Plastics
3.27−0.22 (−6.30%)
Volume
TRY 120.3M
Day range
3.16 – 3.51
Previous close
3.49
Market cap
TRY 14.7B

Last updated: Source: Borsa Istanbul, 15-minute delayed

At a Glance: GENIL Stock

  • The GENIL share price was TRY 3.27 as of November 2, 2026, a daily change of −6.30%.
  • According to Yatırımcı.AI data, the company has a market cap of TRY 14.7B, a P/E of 12.13 and a P/B of 1.07.
  • 52-week price range: TRY 3.16 – 13.50; one-year change −74.34%.
  • Latest dividend: gross TRY 0.02 per share paid on August 4, 2026.
  • Latest financial statements: Q3 2026, published on KAP (Public Disclosure Platform) on October 26, 2026.
What is the GENIL share price?

GENIL (Gen İlaç ve Sağlık Ürünleri Sanayi ve Ticaret A.Ş.) was at TRY 3.27 as of November 2, 2026, a daily change of −6.30%. Prices are delayed by 15 minutes.

What are the GENIL P/E and P/B ratios?

GENIL has a market cap of TRY 14.7B, a P/E of 12.13 and a P/B of 1.07. Ratios use the latest financial statements and the current price.

Does GENIL pay a dividend?

Latest dividend: gross TRY 0.02 per share paid on August 4, 2026.

Key Stats

Day range
3.163.51
52 weeks
3.1613.69
Previous close
3.49
TRY 120.3M
Weighted avg.
3.25
TRY 14.7B
12.13
1.07
Paid-in capital
TRY 4.5B

Set a price alert for GENIL

Add GENIL to your watchlist with a free account and get notified when it reaches your price.

  • Follow funds and stocks in one watchlist
  • An in-app notification and an email when a target is hit
  • 3 active price alerts on the free plan

My Notes

0 / 1000

GENIL Company Profile

Gen İlaç ve Sağlık Ürünleri Sanayi ve Ticaret A.Ş. trades on Borsa Istanbul under the ticker GENIL. Field of activity as filed with KAP (in Turkish): Şirket Esas Sözleşmesinin "Amaç ve Konu" başlıklı 3. maddesine göre Şirketin faaliyet konusu özetle; (1) Tıp ve ilaç sanayinde kullanılan kimyasal maddeler teşhis reaktiflerin, radyoaktif tanı kitlerinin, eczane ve hastane levazımatının alım ve satımını, ithalat ve ihracatını, üretim ve pazarlamasını, taahhüt işlerini, mümessilliğini ve acenteliğini yapmak, (2) Tıp ve veterinerlikte kullanılan tedavi ve teşhis amaçlı ilaç ve müstahzarların alım ve satımını, ithalatını ve ihracatını, üretim ve pazarlamasını, taahhüt işlerini, mümessilliğini ve acenteliğini yapmak, (3) İlaç ve tıpta kullanılan laboratuvar cihazları ve sarf malzemelerinin alım ve satımını, ithalatını ve ihracatını, üretim ve pazarlamasını, taahhüt işlerini, mümessilliğini ve acenteliğini yapmak.

Head office
Mustafa Kemal Mah. 2131 Cad. No:15 İç Kapı No:1 Çankaya / Ankara
Chair of the board
Abidin Gülmüş
Genel Müdür Yar. (Global Satış - Pazarlama)
Selçuk Deniz Karagülle
Genel Müdür Yar. (Medikal, Ar-Ge ve Klinik Operasyonlar)
Nadir Ulu
Subsidiaries and affiliates
11 companies

Shareholder structure

Abidin Gülmüş
64.32%
Ali Göl
9.01%
Other
26.67%

GENIL Price Performance

1 week
−18.25%
1 month
−44.10%
3 months
−63.81%
Year to date
−75.31%
1 year
−74.34%
52-week high
13.50
52-week low
3.16
Distance from 52-week high
−75.77%
Volume vs 20-session average
0.2×
Rank among the day’s losers
83 / 626
Rank by traded value
69 / 626

GENIL Stock Summary (Nov 2, 2026)

Gen İlaç ve Sağlık Ürünleri Sanayi ve Ticaret A.Ş. (GENIL) traded at TRY 3.27 as of 02/11/2026, a daily change of −6.30%. In the 02/11/2026 session, GENIL ranked #83 among the top losers and #69 by traded value out of 626 traded stocks. The share price changed −18.25% over the past week, −44.10% over the past month, −75.31% year to date and −74.34% over the past year. The 52-week trading range is TRY 3.16 – 13.50. The last close is 75.77% below the 52-week high. The company has a market cap of TRY 14.7B, a P/E ratio of 12.13, a P/B ratio of 1.07 and a free float of 22.84%. The stock belongs to the Chemicals, Petroleum, Rubber and Plastics sector, trades on the Main Market and is a constituent of the BIST 500, BIST All Shares, XTUMY, BIST Main Market indices. There is no current price target from at least 2 brokers in the last 9 months. Our AI fair value model estimates TRY 10.29 (214.59%); model date July 21, 2026. Latest KAP disclosure (November 2, 2026): Pay Bazında Devre Kesici Bildirimi.

Frequently Asked Questions

There is no current price target for GENIL from at least 2 brokers in the last 9 months; stale targets and targets dated before a bonus issue are excluded. Our AI fair value model estimates TRY 10.29 (214.59%).

In the 02/11/2026 session GENIL traded at TRY 3.27, a daily change of −6.30%, with a day range of TRY 3.16 – 3.51 and a turnover of TRY 120.3M. Previous close: TRY 3.49. Data is delayed by 15 minutes.

GENIL (Gen İlaç ve Sağlık Ürünleri Sanayi ve Ticaret A.Ş.) is at TRY 3.27 as of 02/11/2026, a daily change of −6.30%. Prices are delayed by 15 minutes; live prices require a Plus membership.

Gen İlaç ve Sağlık Ürünleri Sanayi ve Ticaret A.Ş. trades on Borsa Istanbul under the ticker GENIL. Field of activity as filed with KAP (in Turkish): Şirket Esas Sözleşmesinin "Amaç ve Konu" başlıklı 3. maddesine göre Şirketin faaliyet konusu özetle; (1) Tıp ve ilaç sanayinde kullanılan kimyasal maddeler teşhis reaktiflerin, radyoaktif tanı kitlerinin, eczane ve hastane levazımatının alım ve satımını, ithalat ve ihracatını, üretim ve pazarlamasını, taahhüt işlerini, mümessilliğini ve acenteliğini yapmak, (2) Tıp ve veterinerlikte kullanılan tedavi ve teşhis amaçlı ilaç ve müstahzarların alım ve satımını, ithalatını ve ihracatını, üretim ve pazarlamasını, taahhüt işlerini, mümessilliğini ve acenteliğini yapmak, (3) İlaç ve tıpta kullanılan laboratuvar cihazları ve sarf malzemelerinin alım ve satımını, ithalatını ve ihracatını, üretim ve pazarlamasını, taahhüt işlerini, mümessilliğini ve acenteliğini yapmak. Head office: Mustafa Kemal Mah. 2131 Cad. No:15 İç Kapı No:1 Çankaya / Ankara. Chair of the board: Abidin Gülmüş. Genel Müdür Yar. (Global Satış - Pazarlama): Selçuk Deniz Karagülle. Genel Müdür Yar. (Medikal, Ar-Ge ve Klinik Operasyonlar): Nadir Ulu.

According to the capital structure filed with KAP, the shareholders of GENIL are: Abidin Gülmüş (64.32%), Ali Göl (9.01%), Other (26.67%).

The share price changed −18.25% over the past week, −44.10% over the past month, −75.31% year to date and −74.34% over the past year. The 52-week trading range is TRY 3.16 – 13.50. The last close is 75.77% below the 52-week high.

GENIL has a market cap of TRY 14.7B, a P/E ratio of 12.13, a P/B ratio of 1.07 and an EV/EBITDA of 5.56. Ratios use the latest reported financial statements and the current price.

Gen İlaç ve Sağlık Ürünleri Sanayi ve Ticaret A.Ş. trades in the Chemicals, Petroleum, Rubber and Plastics sector on the Main Market market. Its indices: BIST 500, BIST All Shares, XTUMY, BIST Main Market, BIST Dividend, BIST Participation All, XKTMT, XUGRA, BIST Services, BIST Wholesale and Retail Trade, XTTIC, XSANK.

Yes. As of Nov 2, 2026, GENIL is a constituent of the Borsa Istanbul participation indices, which cover companies that comply with interest-free finance principles: BIST Participation All. The current index period is October 2026–April 2027. Borsa Istanbul reviews participation index membership for the May–September and October–April periods; this is not investment advice.

The trailing dividend yield of GENIL is calculated at 0.17%.

Our fair value model estimates TRY 10.29 for GENIL, a difference of 214.59% from the current price. The model was updated on July 21, 2026. This is not investment advice.

Stocks trading alongside GENIL in the Chemicals, Petroleum, Rubber and Plastics sector: TUPRS, GUBRF, SASA, PETKM, AKSA, ECILC, BRISA, ORZAX.

Price, ratio and company data come from IdealData, a licensed Borsa Istanbul data vendor; analyst targets from broker research; AI indicators from Yatırımcı.AI models. Prices are delayed 15 minutes, ratios refresh daily and financial statements after each KAP disclosure.

Participation index coverage: Borsa Istanbul

Prepared by: Yatırımcı.AI Research TeamLast reviewed: Method: MethodologyEditorial policy